The state-owned pharmaceutical enterprise Saidal finalized a landmark partnership on Monday in Algiers with the German medical corporation Boehringer Ingelheim, paving the way to localize the formulation and commercial manufacturing of a revolutionary therapy designed to manage pulmonary fibrosis.
The official signing ceremony took place at Saidal’s specialized production complex in El Harrach, under the guidance of the Minister of Pharmaceutical Industry, Dr. Wassim Kouidri, alongside the Ambassador of the Federal Republic of Germany to Algeria, Georg Felsheim. The covenant was formally executed by Saidal’s Managing Director, Professor Mourad Belkhelfa, and Boehringer Ingelheim’s Managing Director for India, the Middle East, and Africa, Derek O’Leary, ahead of an audience of senior executives representing both organizations.
This strategic layout aligns directly with national blueprints designed to cultivate domestic pharmaceutical infrastructure, lower sovereign import expenditures, and guarantee the accessibility of cutting-edge medications within the domestic marketplace. The transaction underscores a clear regulatory drive to encourage high-value technological transfers and forge sophisticated industrial collaborations.
Per the operational terms of the venture, the specialized treatment for pulmonary fibrosis will be produced entirely within Saidal’s manufacturing units in El Harrach. Equipped with advanced machinery matching the highest global benchmarks, this site will not only secure a steady domestic supply of the prescription drug but will also facilitate the systematic transfer of specialized technical know-how and clinical engineering competencies to Algerian professionals.
The specific treatment targets advanced fibrotic lung diseases, chronic and progressive medical conditions that are frequently highly complex and occasionally classified as rare. The therapeutic action is formulated to slow down the progression of tissue damage and significantly enhance patient health outcomes, making localized affordability an essential component for specialized clinical care across the country.
For healthcare policymakers, this initiative represents a major step forward in delivering novel medical treatments for specialized conditions. It sets a national precedent for onshore manufacturing of advanced therapeutic solutions aimed at progressive pulmonary fibrotic diseases, laying a firm foundation for future high-tech pharmaceutical projects.
Marking the occasion, Saidal Managing Director Mourad Belkhelfa stated that this deal fits perfectly into the corporation’s roadmap to prioritize local synthesis of innovative therapeutics and build strong domestic pharmaceutical capabilities, which directly serves to anchor national health security.
Concurrently, Derek O’Leary noted that this pact highlights Boehringer Ingelheim’s ongoing commitment to supporting Algeria’s transition toward an innovation-backed healthcare sector, accomplished through localized industrial output and by providing patients with expanded access to high-quality, contemporary medical care.